
  
    
      
        Synopsis_NNP
        
          Introduction_NNP
          Chemoprevention_NNP has_VBZ been_VBN defined_VBN as_IN the_DT use_NN of_IN
          noncytotoxic_JJ nutrients_NNS or_CC pharmacologic_JJ agents_NNS to_TO enhance_VB
          intrinsic_JJ physiologic_JJ mechanisms_NNS that_WDT protect_VBP the_DT
          organism_NN against_IN the_DT development_NN of_IN mutant_JJ clones_NNS and_CC
          their_PRP$ progression_NN to_TO malignant_JJ cancer_NN ._. In_IN a_DT recent_JJ
          landmark_NN trial_NN ,_, tamoxifen_NN ,_, a_DT hormonally_RB active_JJ selective_JJ
          estrogen_NN receptor_NN modulator_NN (_( SERM_NNP )_) ,_, was_VBD shown_VBN to_TO decrease_VB
          the_DT risk_NN of_IN invasive_JJ breast_NN cancer_NN by_IN 49_CD %_NN in_IN
          asymptomatic_JJ ,_, but_CC at-risk_JJ women_NNS [_NN 1_CD ]_NN ._. The_DT search_NN is_VBZ now_RB
          on_IN for_IN agents_NNS with_IN improved_VBN risk-benefit_JJ profiles_NNS ,_, and_CC
          for_IN agents_NNS that_WDT will_MD prevent_VB the_DT subclass_NNS of_IN estrogen_NN
          receptor-negative_JJ tumors_NNS ,_, the_DT incidence_NN of_IN which_WDT was_VBD
          unaffected_JJ by_IN the_DT SERMS_NNP ._. Retinoids_NNP have_VBP already_RB shown_VBN
          potential_JJ in_IN this_DT regard_NN [_NN 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._. Because_IN it_PRP
          will_MD not_RB be_VB possible_JJ to_TO test_VB many_JJ agents_NNS in_IN large_JJ
          randomized_JJ clinical_JJ trials_NNS ,_, efforts_NNS are_VBP underway_NN to_TO
          develop_VB useful_JJ tissue-based_JJ surrogate_JJ end-point_JJ
          biomarkers_NNS that_WDT can_MD be_VB used_VBN to_TO select_VB only_RB the_DT most_RBS
          promising_JJ agents_NNS (_( and_CC doses_NNS )_) for_IN large-scale_JJ trials_NNS ._.
          Provocative_NNP mechanistic_JJ connections_NNS have_VBP been_VBN made_VBN
          between_IN the_DT steroid_NN hormone_NN superfamily_RB ,_, including_VBG the_DT
          SERMS_NNP and_CC retinoids_NNS ,_, and_CC the_DT TGF-β_NNP family_NN of_IN
          multifunctional_NN growth_NN factors_NNS [_NN 8_CD ]_NN ._. The_DT TGF-β_NNP system_NN has_VBZ
          tumor_NN suppressor_NN activity_NN ,_, and_CC loss_NN of_IN TGF-β_NNP response_NN is_VBZ
          associated_VBN with_IN advanced_JJ disease_NN in_IN many_JJ human_JJ tumor_NN
          types_NNS ,_, including_VBG the_DT breast_NN [_NN 9_CD ,_, 10_CD ]_NN ._. Conversely_RB ,_,
          experimental_JJ overexpression_NN of_IN TGF-β_NNP in_IN the_DT mammary_JJ gland_NN
          protects_VBZ against_IN tumorigenesis_NNS [_NN 11_CD ]_NN ._. This_DT strongly_RB
          suggests_VBZ that_IN interventions_NNS that_WDT enhance_VB TGF-β_NNP function_NN
          early_RB in_IN tumorigenesis_NNS could_MD delay_VB or_CC prevent_VB the_DT course_NN
          of_IN the_DT disease_NN ._. SERMs_NNP such_JJ as_IN tamoxifen_NN can_MD upregulate_NN
          TGF-β_NNP production_NN and_CC activation_NN by_IN many_JJ cell_NN types_NNS ,_,
          including_VBG human_JJ breast_NN cancer_NN cell_NN lines_NNS [_NN 12_CD ,_, 13_CD ,_, 14_CD ,_,
          15_CD ]_NN ._. Similarly_RB ,_, retinoids_NNS can_MD upregulate_NN TGF-β_NNP production_NN
          and_CC activation_NN ,_, both_DT in_IN cell_NN culture_NN and_CC in_IN rats_NNS 
          in_IN vivo_NN [_NN 16_CD ,_, 17_CD ]_NN ._. It_PRP is_VBZ plausible_JJ ,_,
          therefore_RB ,_, that_DT upregulation_NN of_IN endogenous_JJ TGF-β_NNP could_MD
          contribute_VB to_TO the_DT chemopreventive_JJ efficacy_NN of_IN SERMs_NNP and_CC
          retinoids_NNS ._.
          In_IN the_DT present_JJ study_NN we_PRP used_VBD a_DT carcinogen-induced_JJ rat_NN
          mammary_JJ carcinogenesis_NNS model_NN to_TO test_VB the_DT hypothesis_NNS that_WDT
          chemoprevention_NN by_IN tamoxifen_NN and_CC retinoids_NNS is_VBZ associated_VBN
          with_IN local_JJ upregulation_NN of_IN TGF-βs_NNP in_IN the_DT mammary_JJ gland_NN ,_,
          and_CC that_IN TGF-βs_NNP might_MD therefore_RB be_VB useful_JJ as_IN potential_JJ
          surrogate_JJ end-point_JJ biomarkers_NNS of_IN chemopreventive_JJ
          efficacy_NN in_IN clinical_JJ trials_NNS ._.
        
        
          Materials_NNS and_CC methods_NNS
          A_DT standard_JJ protocol_NN for_IN induction_NN of_IN breast_NN cancer_NN in_IN
          female_JJ Sprague-_NNP Dawley_NNP rats_NNS using_VBG a_DT single_JJ dose_NN of_IN 
          N_NNP -_: nitroso-_NN 
          N_NNP -_: methylurea_NN (_( NMU_NNP )_) at_IN 8_CD weeks_NNS of_IN
          age_NN was_VBD used_VBN [_NN 4_CD ,_, 18_CD ]_NN ._. Chemopreventive_NNP agents_NNS were_VBD
          incorporated_VBN into_IN powdered_JJ lab_NN chow_NN [_NN 18_CD ]_NN and_CC fed_VBN 
          ad_NN libitum_NN ,_, beginning_VBG 1_CD week_NN after_IN
          injection_NN with_IN NMU_NNP ._. The_DT rats_NNS were_VBD fed_VBN 9_CD cRA_NN (_( Kuraray_NNP
          Company_NNP ,_, Osaka_NNP ,_, Japan_NNP )_) at_IN 120_CD mg_NN /_NN kg_NN of_IN diet_NN ,_, tamoxifen_NN
          (_( Sigma_NNP Chemical_NNP Co_NNP ,_, St_NNP Louis_NNP ,_, MO_NNP ,_, USA_NNP )_) at_IN 1_CD ._. 0_CD mg_NN /_NN kg_NN of_IN
          diet_NN ,_, and_CC 4_CD -_: HPR_NNP (_( RW_NNP Johnson_NNP Pharmaceutical_NNP Research_NNP Unit_NNP ,_,
          Spring_NNP House_NNP ,_, PA_NNP ,_, USA_NNP )_) at_IN 782_CD mg_NN /_NN kg_NN of_IN diet_NN ._.
          Rats_NNP were_VBD weighed_VBN and_CC palpated_JJ for_IN the_DT presence_NN of_IN
          mammary_JJ tumors_NNS weekly_JJ ,_, and_CC six_CD rats_NNS in_IN each_DT experimental_JJ
          group_NN were_VBD sacrificed_JJ after_IN 6_CD and_CC 12_CD weeks_NNS of_IN treatment_NN
          with_IN chemopreventive_JJ agent_NN ._. For_IN experiments_NNS to_TO determine_VB
          the_DT effect_NN of_IN high_JJ doses_NNS of_IN tamoxifen_NN administered_VBN over_IN
          shorter_JJR periods_NNS of_IN time_NN ,_, rats_NNS were_VBD given_VBN 10_CD mg_NN
          tamoxifen_NN /_NN kg_NN body_NN weight_NN per_IN day_NN intragastrically_RB ,_, or_CC 1_CD
          mg_NN tamoxifen_NN /_NN kg_NN in_IN the_DT diet_NN ,_, and_CC were_VBD sacrificed_JJ after_IN 1_CD
          day_NN or_CC 3_CD weeks_NNS of_IN treatment_NN ._. All_DT palpated_JJ tumors_NNS were_VBD
          confirmed_VBN at_IN necropsy_NN ,_, and_CC mammary_JJ glands_NNS were_VBD fixed_VBN in_IN
          neutral_JJ buffered_JJ formalin_NN and_CC embedded_VBN in_IN paraffin_NN ._. The_DT
          number_NN 2_CD (_( first_JJ thoracic_JJ )_) mammary_JJ gland_NN was_VBD sectioned_JJ for_IN
          histology_NN and_CC immunohistochemistry_NN ._.
          Immunohistochemical_NNP staining_VBG was_VBD done_VBN using_VBG rabbit_NN
          polyclonal_NN antibodies_NNS raised_VBD against_IN synthetic_JJ peptides_NNS
          that_WDT correspond_VB to_TO regions_NNS in_IN the_DT mature_VBP forms_NNS of_IN TGF-β_NNP 
          1_CD ,_, TGF-β_NNP 
          2_CD and_CC TGF-β_NNP 
          3_CD :_: anti-_NN TGF-β_NNP 
          1_CD -_: LC_NNP and_CC anti-_NN TGF-β_NNP 
          1_CD -_: CC_NNP [_NN 19_CD ]_NN ,_, anti-_NN TGF-β_NNP 
          2_CD (_( sc-_NN 90_CD ;_: Santa_NNP Cruz_NNP Biotechnologies_NNP
          Inc_NNP ,_, Santa_NNP Cruz_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, and_CC anti-_NN 50_CD -_: 60_CD -_: β_NN 
          3_CD -_: LC_NNP [_NN 20_CD ]_NN ,_, respectively_RB ._. Anti-latent_NNP
          TGF-β-binding_NNP protein_NN (_( LTBP_NNP ;_: Ab_NNP 39_CD )_) was_VBD raised_VBN against_IN the_DT
          purified_JJ full-length_JJ platelet_NN LTBP_NNP [_NN 21_CD ]_NN ._. The_DT antibodies_NNS
          were_VBD affinity_NN purified_JJ against_IN the_DT immunizing_VBG peptide_NN
          (_( anti-_NN TGF-β_NNP 
          3_LS )_) or_CC against_IN protein_NN A_DT sepharose_NN
          (_( anti-_NN TGF-β_NNP 
          1_CD -_: LC_NNP ,_, anti-_NN TGF-β_NNP 
          1_CD -_: CC_NNP and_CC anti-_NN TGF-β_NNP 
          2_LS )_) ._. Immunohistochemical_NNP staining_VBG was_VBD
          performed_VBN using_VBG an_DT indirect_JJ immunoperoxidase_NN detection_NN
          protocol_NN (_( Vectastain_NNP Elite_NNP kit_NN ,_, Vector_NNP Laboratories_NNPS ,_,
          Burlingame_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Staining_NNP intensity_NN was_VBD scored_VBN on_IN a_DT
          scale_NN of_IN 0_CD -_: 4_CD +_NN ,_, using_VBG the_DT mouse_NN embryo_NN control_NN section_NN as_IN
          a_DT reference_NN standard_JJ for_IN each_DT run_NN ._. Ducts_NNP and_CC periductal_NN
          stroma_NN were_VBD scored_VBN independently_RB ._. Staining_NNP was_VBD scored_VBN in_IN
          a_DT blinded_JJ manner_NN by_IN two_CD independent_JJ observers_NNS ,_, and_CC
          discrepancies_NNS were_VBD rescored_JJ by_IN consensus_NN ._. Staining_NNP
          intensity_NN was_VBD plotted_VBD as_IN the_DT mean_JJ ±_NN standard_JJ deviation_NN
          for_IN each_DT experimental_JJ group_NN ._.
        
        
          Results_NNS
          Palpable_NNP mammary_JJ tumors_NNS were_VBD first_RB detected_VBD after_IN
          approximately_RB 35_CD days_NNS following_VBG initiation_NN of_IN NMU_NNP ,_, and_CC by_IN
          70_CD days_NNS incidence_NN had_VBD reached_VBN 100_CD %_NN in_IN rats_NNS not_RB treated_VBN
          with_IN chemopreventive_JJ agents_NNS (_( Fig_NNP ._. 1_LS a_DT )_) ._. Tamoxifen_NNP ,_, alone_RB
          or_CC in_IN combination_NN with_IN retinoids_NNS ,_, decreased_VBD tumor_NN
          incidence_NN by_IN more_JJR than_IN 70_CD %_NN by_IN the_DT end_NN of_IN the_DT study_NN ,_,
          whereas_IN 9_CD cRA_NN alone_RB decreased_VBD it_PRP by_IN 50_CD %_NN ._. 4_LS -_: HPR_NNP alone_RB had_VBD a_DT
          relatively_RB modest_JJ effect_NN on_IN tumor_NN incidence_NN in_IN the_DT
          present_JJ study_NN ._. However_RB ,_, it_PRP significantly_RB decreased_VBD tumor_NN
          multiplicity_NN (_( Fig_NNP ._. 1_LS b_SYM )_) ,_, indicating_VBG that_IN the_DT dose_NN used_VBN was_VBD
          efficacious_JJ ._. There_EX was_VBD minimal_JJ toxicity_NN associated_VBN with_IN
          the_DT chemopreventive_JJ intervention_NN ,_, except_IN in_IN the_DT tamoxifen_NN
          +_NN 4_CD -_: HPR_NNP group_NN ,_, in_IN which_WDT mild_JJ toxicity_NN was_VBD observed_VBN ,_, as_IN
          judged_VBN by_IN the_DT weights_NNS of_IN the_DT experimental_JJ animals_NNS (_( Fig_NNP ._.
          1_LS c_SYM )_) ._.
          None_NN of_IN the_DT chemopreventive_JJ agents_NNS used_VBN ,_, alone_RB or_CC in_IN
          combination_NN ,_, were_VBD found_VBN to_TO affect_VB expression_NN of_IN any_DT of_IN
          the_DT TGF-β_NNP isoforms_NNS or_CC the_DT LTBP_NNP in_IN either_DT ductal_NN
          epithelium_NN or_CC periductal_NN stroma_NN after_IN 6_CD weeks_NNS of_IN
          chemopreventive_JJ intervention_NN (_( Fig_NNP ._. 3_LS )_) ._. The_DT 6_CD -_: week_NN time_NN
          point_NN was_VBD chosen_VBN as_IN representative_NN of_IN the_DT period_NN of_IN
          preneoplasia_NN ,_, as_IN the_DT majority_NN of_IN the_DT animals_NNS had_VBD no_DT
          palpable_JJ tumors_NNS at_IN this_DT time_NN (_( Fig_NNP ._. 1_LS )_) ._. In_IN the_DT study_NN set_VBD ,_,
          eight_CD out_IN of_IN 36_CD (_( 22_CD %_NN )_) of_IN the_DT slides_NNS showed_VBD histologic_JJ
          evidence_NN of_IN hyperplasia_NN ,_, one_CD out_IN of_IN 36_CD had_VBD a_DT ductal_NN
          carcinoma_NN 
          in_IN situ_NN (_( mammary_JJ intraepithelial_NN
          neoplasia_NN [_NN 22_CD ]_NN )_) ,_, and_CC one_CD out_IN of_IN 36_CD had_VBD a_DT carcinoma_NN ._. We_PRP
          further_RBR investigated_VBD the_DT effect_NN of_IN tamoxifen_NN at_IN higher_JJR
          doses_NNS and_CC earlier_JJR time_NN points_NNS ._. In_IN rats_NNS that_WDT received_JJ
          tamoxifen_NN at_IN 10_CD mg_NN /_NN kg_NN per_IN day_NN intragastrically_RB
          (_( equivalent_JJ to_TO 600_CD mg_NN /_NN day_NN for_IN a_DT human_JJ )_) or_CC 1_CD mg_NN /_NN kg_NN per_IN day_NN
          intragastrically_RB (_( equivalent_JJ to_TO 60_CD mg_NN /_NN day_NN for_IN a_DT human_JJ )_)
          for_IN either_DT 1_CD day_NN or_CC 3_CD weeks_NNS ,_, again_RB no_DT consistent_JJ changes_NNS
          were_VBD seen_VBN in_IN TGF-β_NNP expression_NN ,_, using_VBG either_CC the_DT TGF-β_NNP 
          1_CD -_: CC_NNP or_CC the_DT TGF-β_NNP 
          2_CD antibodies_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Discussion_NNP
          One_CD major_JJ goal_NN in_IN the_DT field_NN of_IN prevention_NN is_VBZ the_DT
          identification_NN of_IN surrogate_JJ biomarkers_NNS that_WDT might_MD rapidly_RB
          predict_VB the_DT effect_NN of_IN a_DT given_VBN agent_NN on_IN the_DT primary_JJ
          end-point_JJ of_IN cancer_NN incidence_NN ._. The_DT most_RBS informative_JJ
          markers_NNS are_VBP those_DT with_IN modulation_NN that_WDT is_VBZ likely_JJ to_TO be_VB
          directly_RB related_VBN to_TO the_DT preventive_JJ effect_NN ,_, and_CC a_DT
          compelling_JJ argument_NN can_MD be_VB made_VBN that_IN TGF-βs_NNP may_MD fall_VB into_IN
          this_DT category_NN ._. However_RB ,_, the_DT present_JJ data_NN in_IN a_DT
          well-established_JJ preclinical_JJ model_NN of_IN breast_NN cancer_NN ,_,
          employing_VBG a_DT variety_NN of_IN highly_RB effective_JJ chemopreventive_JJ
          regimens_NNS ,_, suggest_VBP that_IN this_DT is_VBZ not_RB the_DT case_NN ._.
          Most_JJS of_IN the_DT previous_JJ studies_NNS on_IN the_DT regulation_NN of_IN
          TGF-βs_NNP by_IN tamoxifen_NN and_CC retinoids_NNS have_VBP been_VBN done_VBN in_IN
          tissue_NN culture_NN [_NN 12_CD ,_, 13_CD ,_, 14_CD ,_, 17_CD ]_NN ._. The_DT lack_NN of_IN effect_NN on_IN
          TGF-β_NNP expression_NN in_IN the_DT present_NN 
          in_IN vivo_NN study_NN may_MD reflect_VB the_DT
          dependence_NN of_IN the_DT response_NN on_IN contextual_NN cues_NNS that_WDT are_VBP
          only_RB present_JJ in_IN the_DT artificial_NN 
          in_IN vitro_NN environment_NN ._. In_IN an_DT 
          in_IN vivo_NN study_NN [_NN 16_CD ]_NN ,_, all-_NN 
          trans_NNS -_: retinoic_JJ acid_NN was_VBD shown_VBN to_TO
          cause_VB an_DT upregulation_NN of_IN TGF-β_NNP isoforms_NNS in_IN rats_NNS ,_, with_IN
          kinetics_NNS and_CC isoform_NN selectivity_NN that_WDT varied_VBD with_IN the_DT
          target_NN tissue_NN ._. However_RB ,_, the_DT rats_NNS were_VBD vitamin_NN
          A-_NNP deficient_NN ,_, and_CC it_PRP is_VBZ not_RB known_VBN whether_IN the_DT same_JJ effects_NNS
          would_MD be_VB seen_VBN in_IN vitamin_NN A-_NNP replete_JJ animals_NNS such_JJ as_IN were_VBD
          used_VBN in_IN the_DT present_JJ study_NN ._. In_IN a_DT small_JJ study_NN in_IN humans_NNS [_NN
          23_CD ]_NN tamoxifen_NN treatment_NN was_VBD shown_VBN to_TO cause_VB a_DT consistent_JJ
          induction_NN in_IN extracellular_NN TGF-β_NNP in_IN breast_NN cancer_NN
          biopsies_NNS ,_, when_WRB compared_VBN with_IN pretreatment_NN biopsies_NNS from_IN
          the_DT same_JJ patients_NNS ,_, and_CC complex_JJ effects_NNS of_IN tamoxifen_NN on_IN
          induction_NN of_IN TGF-β_NNP 
          2_CD in_IN the_DT plasma_NN of_IN patients_NNS with_IN
          metastatic_JJ breast_NN cancer_NN have_VBP been_VBN described_VBN [_NN 24_CD ]_NN ._. It_PRP is_VBZ
          possible_JJ that_DT tamoxifen_NN is_VBZ only_RB effective_JJ in_IN inducing_VBG
          TGF-β_NNP in_IN the_DT context_NN of_IN a_DT tumor_NN ,_, and_CC not_RB in_IN the_DT normal_JJ or_CC
          initiated_VBN tissue_NN that_WDT was_VBD the_DT subject_NN of_IN the_DT present_JJ
          study_NN ._. However_RB ,_, an_DT optimal_NN surrogate_JJ end-point_JJ biomarker_NN
          in_IN a_DT prevention_NN setting_VBG needs_VBZ to_TO be_VB modulated_JJ in_IN normal_JJ
          or_CC premalignant_NN tissues_NNS ._. Although_IN we_PRP cannot_NN eliminate_VBP the_DT
          possibility_NN of_IN more_JJR subtle_JJ effects_NNS of_IN chemopreventive_JJ
          agents_NNS on_IN TGF-β_NNP bioavailability_NN or_CC cellular_JJ
          responsiveness_NNS ,_, in_IN our_PRP$ preliminary_JJ analyses_NNS we_PRP have_VBP seen_VBN
          no_DT effects_NNS on_IN the_DT expression_NN of_IN type_NN I_PRP and_CC type_NN II_NNP TGF-β_NNP
          receptors_NNS (_( data_NNS not_RB shown_VBN )_) ._.
          There_EX is_VBZ considerable_JJ evidence_NN to_TO suggest_VB that_IN ,_, at_IN
          late_JJ stages_NNS in_IN tumorigenesis_NNS ,_, TGF-βs_NNP can_MD actually_RB promote_VB
          the_DT tumorigenic_JJ process_NN ,_, particularly_RB if_IN the_DT epithelial_NN
          cells_NNS have_VBP lost_VBN responsiveness_NNS to_TO the_DT growth_NN inhibitory_NN
          effects_NNS of_IN TGF-β_NNP by_IN this_DT time_NN [_NN 9_CD ]_NN ._. While_IN the_DT present_JJ
          work_NN was_VBD in_IN progress_NN ,_, a_DT study_NN was_VBD reported_VBN [_NN 25_CD ]_NN that_WDT
          showed_VBD that_DT loss_NN of_IN the_DT type_NN II_NNP TGF-β_NNP receptor_NN can_MD
          already_RB be_VB seen_VBN in_IN a_DT significant_JJ fraction_NN of_IN hyperplasias_NNS
          without_IN atypia_NN in_IN the_DT human_JJ breast_NN ._. Furthermore_RB ,_, loss_NN of_IN
          the_DT receptor_NN correlated_JJ with_IN increased_VBN risk_NN of_IN subsequent_JJ
          development_NN of_IN invasive_JJ breast_NN cancer_NN ._. Thus_RB ,_, loss_NN of_IN
          TGF-β_NNP response_NN may_MD be_VB a_DT very_RB early_JJ event_NN in_IN the_DT
          development_NN of_IN human_JJ breast_NN cancer_NN ._. Because_IN locally_RB
          elevated_VBD TGF-β_NNP levels_NNS could_MD select_VB for_IN TGF-β-resistant_NNP
          cells_NNS ,_, and_CC because_IN TGF-βs_NNP can_MD have_VB oncogenic_JJ effects_NNS on_IN
          the_DT stroma_NN ,_, it_PRP may_MD actually_RB be_VB important_JJ for_IN the_DT safety_NN
          profile_NN of_IN chemopreventive_JJ agents_NNS to_TO demonstrate_VB that_IN
          they_PRP do_VBP not_RB increase_VB TGF-β_NNP levels_NNS in_IN the_DT at-risk_JJ breast_NN ._.
          In_IN this_DT regard_NN ,_, this_DT demonstration_NN that_IN the_DT expression_NN of_IN
          TGF-βs_NNP in_IN the_DT preclinical_JJ rat_NN model_NN is_VBZ unaffected_JJ by_IN
          tamoxifen_NN ,_, 9_CD cRA_NN ,_, or_CC 4_CD -_: HPR_NNP may_MD actually_RB have_VB positive_JJ
          implications_NNS ,_, because_IN all_DT three_CD agents_NNS are_VBP already_RB in_IN
          clinical_JJ use_NN ._.
          The_DT NMU-induced_NNP rat_NN model_NN of_IN mammary_JJ tumorigenesis_NNS is_VBZ
          widely_RB used_VBN for_IN chemoprevention_NN studies_NNS ,_, and_CC yields_NNS rapid_JJ
          development_NN of_IN hormonally_RB responsive_JJ mammary_JJ tumors_NNS with_IN
          100_CD %_NN incidence_NN [_NN 2_CD ,_, 4_CD ,_, 18_CD ]_NN ._. To_TO do_VB this_DT ,_, the_DT initiating_VBG
          agent_NN is_VBZ given_VBN at_IN 8_CD weeks_NNS of_IN age_NN and_CC the_DT chemopreventive_JJ
          agent_NN is_VBZ started_VBN a_DT week_NN later_RB ,_, during_IN the_DT period_NN of_IN
          active_JJ development_NN of_IN the_DT mammary_JJ gland_NN ._. We_PRP observed_VBD that_IN
          the_DT histology_NN of_IN the_DT tamoxifen-treated_JJ mammary_JJ glands_NNS
          differed_VBD significantly_RB from_IN control_NN glands_NNS when_WRB examined_VBD
          after_IN 6_CD weeks_NNS of_IN tamoxifen_NN treatment_NN ,_, showing_VBG fewer_JJR
          terminal_NN end-buds_JJ and_CC less_RBR tertiary_JJ branching_VBG ._. Part_NN of_IN
          the_DT chemopreventive_JJ efficacy_NN of_IN antiestrogens_NNS and_CC
          retinoids_NNS in_IN this_DT model_NN may_MD therefore_RB be_VB due_JJ to_TO a_DT
          generalized_JJ decrease_NN in_IN ductal_NN development_NN ._. Since_IN
          chemopreventive_JJ agents_NNS are_VBP unlikely_JJ to_TO be_VB given_VBN to_TO humans_NNS
          during_IN the_DT pubertal_NN period_NN ,_, this_DT form_NN of_IN preclinical_JJ
          model_NN may_MD not_RB accurately_RB reflect_VB the_DT degree_NN of_IN
          chemopreventive_JJ benefit_NN that_WDT could_MD be_VB achieved_VBN in_IN humans_NNS ._.
          Although_IN the_DT accelerated_VBN time_NN course_NN and_CC high_JJ penetrance_NN
          of_IN disease_NN reduces_VBZ the_DT costs_NNS of_IN this_DT model_NN ,_, it_PRP may_MD be_VB
          advisable_JJ to_TO confirm_VB efficacy_NN of_IN promising_JJ agents_NNS in_IN a_DT
          model_NN that_IN delays_NNS application_NN of_IN the_DT chemopreventive_JJ
          agent_NN until_IN the_DT mammary_JJ gland_NN is_VBZ fully_RB developed_VBN ._.
          In_IN conclusion_NN ,_, we_PRP have_VBP shown_VBN that_DT treatment_NN of_IN rats_NNS
          with_IN tamoxifen_NN or_CC retinoids_NNS results_NNS in_IN effective_JJ
          chemoprevention_NN of_IN mammary_JJ tumorigenesis_NNS ,_, without_IN any_DT
          detectable_JJ effect_NN on_IN local_JJ expression_NN of_IN TGF-βs_NNP ._. Although_IN
          we_PRP cannot_NN rule_NN out_IN more_JJR subtle_JJ effects_NNS on_IN TGF-β_NNP activity_NN ,_,
          such_JJ as_IN the_DT activation_NN of_IN latent_NN forms_NNS ,_, the_DT data_NNS suggest_VBP
          that_IN TGF-βs_NNP are_VBP not_RB involved_VBN in_IN the_DT underlying_VBG molecular_JJ
          mechanism_NN of_IN chemoprevention_NN induced_VBN by_IN these_DT agents_NNS ._.
          This_DT agrees_VBZ with_IN 
          in_IN vitro_NN work_NN [_NN 26_CD ]_NN that_WDT showed_VBD
          that_DT blockade_NN of_IN TGF-β_NNP signaling_VBG did_VBD not_RB abrogate_NN the_DT
          growth_NN inhibitory_NN effect_NN of_IN tamoxifen_NN on_IN breast_NN cancer_NN
          cells_NNS ._. Given_VBN the_DT very_RB limited_JJ breast_NN tissue_NN available_JJ in_IN
          clinical_JJ trials_NNS ,_, we_PRP do_VBP not_RB recommend_VB testing_NN for_IN TGF-βs_NNP
          as_IN a_DT surrogate_JJ end-point_JJ biomarkers_NNS at_IN this_DT time_NN ._.
          All_DT three_CD TGF-β_NNP isoforms_NNS and_CC the_DT LTBP_NNP (_( part_NN of_IN the_DT
          naturally_RB occurring_VBG latent_NN TGF-β_NNP complex_JJ )_) showed_VBD broadly_RB
          similar_JJ immunostaining_VBG patterns_NNS in_IN the_DT mammary_JJ glands_NNS of_IN
          untreated_JJ rats_NNS at_IN 15_CD weeks_NNS of_IN age_NN (_( Fig_NNP ._. 2_LS )_) ._. They_PRP were_VBD
          present_VB both_DT in_IN the_DT ductal_NN epithelium_NN and_CC in_IN the_DT
          periductal_NN stroma_NN ,_, suggesting_VBG that_IN the_DT TGF-βs_NNP are_VBP
          synthesized_JJ by_IN the_DT epithelial_NN cells_NNS ,_, and_CC possibly_RB stromal_NN
          cells_NNS ,_, and_CC are_VBP sequestered_VBN in_IN the_DT extracellular_NN matrix_NN ._.
          This_DT staining_VBG pattern_NN is_VBZ consistent_JJ with_IN a_DT role_NN for_IN the_DT
          TGF-βs_NNP in_IN the_DT maintenance_NN of_IN normal_JJ mammary_JJ
          homeostasis_NNS ._.
          After_IN 6_CD weeks_NNS of_IN treatment_NN ,_, we_PRP noticed_VBD that_IN mammary_JJ
          glands_NNS from_IN tamoxifen-treated_JJ rats_NNS were_VBD less_RBR developed_JJ
          than_IN those_DT of_IN untreated_JJ control_NN animals_NNS ,_, having_VBG fewer_RBR
          tertiary_JJ ducts_NNS and_CC terminal_NN end_NN buds_NNS ,_, and_CC they_PRP could_MD
          consistently_RB be_VB identified_VBN from_IN a_DT blind_JJ data_NN set_VBN (_( Fig_NNP ._.
          4_LS )_) ._. By_IN 12_CD weeks_NNS of_IN treatment_NN ,_, all_DT three_CD chemopreventive_JJ
          agents_NNS had_VBD a_DT significant_JJ effect_NN on_IN glandular_NN histology_NN ,_,
          with_IN tamoxifen_NN and_CC 9_CD cRA_NN showing_VBG the_DT greatest_JJS suppression_NN
          of_IN ductal_NN development_NN and_CC lobule_NN formation_NN ,_, and_CC 4_CD -_: HPR_NNP
          showing_VBG a_DT relatively_RB mild_JJ effect_NN ._.
        
      
      
        Full_NNP article_NN
        
          Introduction_NNP
          Chemoprevention_NNP has_VBZ been_VBN defined_VBN as_IN the_DT use_NN of_IN
          noncytotoxic_JJ nutrients_NNS or_CC pharmacologic_JJ agents_NNS to_TO enhance_VB
          intrinsic_JJ physiologic_JJ mechanisms_NNS that_WDT protect_VBP the_DT
          organism_NN against_IN the_DT development_NN of_IN mutant_JJ clones_NNS and_CC
          their_PRP$ progression_NN to_TO malignant_JJ cancer_NN [_NN 27_CD ]_NN ._. Members_NNS of_IN
          the_DT nuclear_JJ receptor_NN superfamily_RB are_VBP considered_VBN to_TO be_VB
          particularly_RB promising_JJ targets_NNS for_IN chemoprevention_NN ,_,
          because_IN of_IN their_PRP$ pivotal_JJ role_NN in_IN the_DT regulation_NN of_IN
          metabolic_JJ ,_, developmental_NN ,_, and_CC differentiation_NN pathways_NNS [_NN
          28_CD ]_NN ._. In_IN a_DT recent_JJ landmark_NN trial_NN [_NN 1_CD ]_NN ,_, tamoxifen_NN ,_, a_DT
          hormonally_RB active_JJ SERM_NNP ,_, was_VBD shown_VBN to_TO decrease_VB the_DT risk_NN of_IN
          invasive_JJ breast_NN cancer_NN by_IN 49_CD %_NN in_IN asymptomatic_JJ ,_, but_CC
          at-risk_JJ women_NNS ._. Another_DT SERM_NNP ,_, raloxifene_NN ,_, also_RB shows_VBZ
          promise_NN [_NN 29_CD ]_NN ._. These_DT studies_NNS validate_NN the_DT concept_NN of_IN
          using_VBG pharmacologic_JJ agents_NNS for_IN prevention_NN of_IN human_JJ breast_NN
          cancer_NN in_IN apparently_RB healthy_JJ individuals_NNS ._.
          The_DT search_NN is_VBZ now_RB on_IN for_IN agents_NNS with_IN improved_VBN
          risk-benefit_JJ profiles_NNS ,_, and_CC for_IN agents_NNS that_WDT will_MD prevent_VB
          the_DT subclass_NNS of_IN estrogen_NN receptor-negative_JJ tumors_NNS ,_, the_DT
          incidence_NN of_IN which_WDT was_VBD unaffected_JJ by_IN the_DT SERMS_NNP ._.
          Retinoids_NNP ,_, a_DT family_NN of_IN compounds_NNS structurally_RB related_VBN to_TO
          vitamin_NN A_DT ,_, have_VBP already_RB shown_VBN potential_JJ in_IN this_DT regard_NN [_NN
          2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._. Since_IN it_PRP will_MD not_RB be_VB possible_JJ to_TO test_VB
          many_JJ agents_NNS in_IN large_JJ randomized_JJ clinical_JJ trials_NNS ,_, efforts_NNS
          are_VBP underway_NN to_TO develop_VB useful_JJ tissue-based_JJ surrogate_JJ
          end-point_JJ biomarkers_NNS that_WDT can_MD be_VB used_VBN to_TO select_VB only_RB the_DT
          most_RBS promising_JJ agents_NNS (_( and_CC doses_NNS )_) for_IN large-scale_JJ
          trials_NNS ._.
          Provocative_NNP mechanistic_JJ connections_NNS have_VBP been_VBN made_VBN
          between_IN the_DT steroid_NN hormone_NN superfamily_RB ,_, including_VBG the_DT
          SERMS_NNP and_CC retinoids_NNS ,_, and_CC the_DT TGF-β_NNP family_NN of_IN
          multifunctional_NN growth_NN factors_NNS ._. TGF-βs_NNP are_VBP potent_JJ
          inhibitors_NNS of_IN the_DT growth_NN of_IN many_JJ epithelial_NN cell_NN types_NNS [_NN
          8_CD ]_NN ._. Recent_JJ work_NN has_VBZ implicated_VBN the_DT TGF-β_NNP system_NN as_IN an_DT
          important_JJ tumor_NN suppressor_NN pathway_NN ,_, and_CC loss_NN of_IN TGF-β_NNP
          response_NN is_VBZ associated_VBN with_IN advanced_JJ disease_NN in_IN many_JJ
          human_JJ tumor_NN types_NNS ,_, including_VBG the_DT breast_NN [_NN 9_CD ,_, 10_CD ,_, 30_CD ,_, 31_CD ]_NN ._.
          In_IN mouse_NN models_NNS ,_, over-expression_JJ of_IN TGF-β_NNP 
          1_CD in_IN the_DT mammary_JJ gland_NN protects_VBZ
          against_IN tumorigenesis_NNS [_NN 11_CD ]_NN ,_, whereas_IN local_JJ inactivation_NN
          of_IN the_DT type_NN II_NNP TGF-β_NNP receptor_NN enhances_VBZ tumorigenesis_NNS [_NN
          32_CD ]_NN ._. This_DT strongly_RB suggests_VBZ that_IN interventions_NNS that_WDT
          enhance_VB TGF-β_NNP function_NN early_RB in_IN tumorigenesis_NNS could_MD delay_VB
          or_CC prevent_VB the_DT course_NN of_IN the_DT disease_NN ._.
          Antiestrogens_NNP such_JJ as_IN tamoxifen_NN have_VBP been_VBN shown_VBN to_TO
          upregulate_NN TGF-β_NNP production_NN and_CC activation_NN by_IN many_JJ cell_NN
          types_NNS ,_, including_VBG human_JJ breast_NN cancer_NN cell_NN lines_NNS [_NN 12_CD ,_, 13_CD ,_,
          14_CD ,_, 15_CD ]_NN ._. Similarly_RB ,_, retinoids_NNS can_MD upregulate_NN TGF-β_NNP
          production_NN and_CC activation_NN ,_, both_DT in_IN cell_NN culture_NN and_CC in_IN
          rats_NNS 
          in_IN vivo_NN [_NN 16_CD ,_, 17_CD ]_NN ._. Therefore_RB ,_, it_PRP is_VBZ
          reasonable_JJ to_TO propose_VB that_IN some_DT of_IN the_DT chemopreventive_JJ
          efficacy_NN of_IN these_DT agents_NNS against_IN breast_NN cancer_NN 
          in_IN vivo_NN could_MD be_VB mediated_JJ via_IN a_DT
          local_JJ upregulation_NN of_IN TGF-βs_NNP ,_, with_IN concomitant_NN
          enhancement_NN of_IN tumor_NN suppressor_NN activity_NN ._.
          In_IN the_DT present_JJ study_NN ,_, we_PRP used_VBD a_DT carcinogen-induced_JJ rat_NN
          model_NN of_IN mammary_JJ carcinogenesis_NNS to_TO test_VB whether_IN
          chemoprevention_NN by_IN tamoxifen_NN and_CC by_IN two_CD different_JJ
          retinoids_NNS (_( 4_CD -_: HPR_NNP ,_, also_RB known_VBN as_IN fenretinide_NN ;_: and_CC 9_CD -_: cRA_NN )_)
          is_VBZ associated_VBN with_IN local_JJ upregulation_NN of_IN TGF-βs_NNP in_IN the_DT
          initiated_VBN mammary_JJ gland_NN ._. If_IN this_DT were_VBD the_DT case_NN ,_, TGF-βs_NNP
          might_MD be_VB useful_JJ as_IN potential_JJ surrogate_JJ end-point_JJ
          biomarkers_NNS in_IN clinical_JJ trials_NNS ._. However_RB ,_, the_DT results_NNS show_VBP
          that_IN TGF-β_NNP levels_NNS ,_, as_IN detected_VBN immunohistochemically_RB ,_, are_VBP
          not_RB affected_VBN by_IN tamoxifen_NN or_CC retinoids_NNS in_IN this_DT
          preclinical_JJ model_NN of_IN early-stage_JJ breast_NN cancer_NN ._.
        
      
      
        Materials_NNS and_CC method_NN
        
          Mammary_NNP carcinogenesis_NNS studies_NNS
          A_DT standard_JJ protocol_NN for_IN induction_NN of_IN breast_NN cancer_NN in_IN
          female_JJ Sprague-_NNP Dawley_NNP rats_NNS was_VBD used_VBN [_NN 4_CD ,_, 18_CD ]_NN ,_, with_IN
          initiation_NN induced_VBN by_IN a_DT single_JJ intravenous_JJ dose_NN of_IN NMU_NNP
          (_( 50_CD mg_NN /_NN kg_NN body_NN weight_NN )_) at_IN 8_CD weeks_NNS of_IN age_NN ._. Retinoids_NNP and_CC
          tamoxifen_NN were_VBD incorporated_VBN into_IN powdered_JJ laboratory_NN chow_NN
          as_IN described_VBN previously_RB [_NN 18_CD ]_NN and_CC fed_VBN 
          ad_NN libitum_NN ,_, beginning_VBG 1_CD week_NN after_IN
          injection_NN with_IN NMU_NNP ._. Rats_NNP were_VBD fed_VBN 9_CD cRA_NN (_( Kuraray_NNP Company_NNP ,_,
          Osaka_NNP ,_, Japan_NNP )_) at_IN 120_CD mg_NN /_NN kg_NN of_IN diet_NN ,_, tamoxifen_NN (_( Sigma_NNP
          Chemical_NNP Co_NNP ,_, St_NNP Louis_NNP ,_, MO_NNP ,_, USA_NNP )_) at_IN 1_CD ._. 0_CD mg_NN /_NN kg_NN of_IN diet_NN ,_, and_CC
          4_CD -_: HPR_NNP (_( RW_NNP Johnson_NNP Pharmaceutical_NNP Research_NNP Institute_NNP )_) at_IN
          782_CD mg_NN /_NN kg_NN of_IN diet_NN ._.
          Rats_NNP were_VBD weighed_VBN weekly_JJ and_CC palpated_JJ for_IN the_DT presence_NN
          of_IN mammary_JJ tumors_NNS ._. Six_CD rats_NNS in_IN each_DT experimental_JJ group_NN
          were_VBD sacrificed_JJ after_IN 6_CD and_CC 12_CD weeks_NNS of_IN treatment_NN with_IN
          chemopreventive_JJ agent_NN ._. The_DT 6_CD -_: week_NN sacrifice_NN time_NN was_VBD
          chosen_VBN for_IN the_DT immunohistochemical_JJ studies_NNS to_TO represent_VB
          the_DT period_NN of_IN premalignancy_NN ,_, because_IN the_DT incidence_NN of_IN
          palpable_JJ tumors_NNS is_VBZ less_JJR than_IN 20_CD %_NN for_IN all_DT experimental_JJ
          groups_NNS at_IN that_DT time_NN ._. By_IN 12_CD weeks_NNS all_DT rats_NNS that_WDT have_VBP not_RB
          received_VBN a_DT chemopreventive_JJ agent_NN have_VBP tumors_NNS ,_, so_IN the_DT
          primary_JJ purpose_NN of_IN the_DT 12_CD -_: week_NN sacrifice_NN time_NN was_VBD to_TO
          allow_VB an_DT accurate_JJ determination_NN of_IN chemopreventive_JJ
          efficacy_NN for_IN the_DT particular_JJ experiment_NN ._.
          For_IN experiments_NNS to_TO determine_VB the_DT effect_NN of_IN high_JJ doses_NNS
          of_IN tamoxifen_NN administered_VBN over_IN shorter_JJR periods_NNS of_IN time_NN ,_,
          rats_NNS were_VBD given_VBN 10_CD mg_NN tamoxifen_NN /_NN kg_NN body_NN weight_NN per_IN day_NN
          intragastrically_RB or_CC 1_CD mg_NN tamoxifen_NN /_NN kg_NN in_IN the_DT diet_NN ,_, and_CC
          were_VBD sacrificed_JJ after_IN 1_CD day_NN or_CC 3_CD weeks_NNS of_IN treatment_NN ._.
          All_DT palpated_JJ tumors_NNS were_VBD confirmed_VBN at_IN necropsy_NN ,_, and_CC
          mammary_JJ glands_NNS were_VBD fixed_VBN in_IN neutral_JJ buffered_JJ formalin_NN
          and_CC embedded_VBN in_IN paraffin_NN ._. The_DT number_NN 2_CD (_( first_JJ thoracic_JJ )_)
          mammary_JJ gland_NN was_VBD sectioned_JJ for_IN histology_NN and_CC
          immunohistochemistry_NN ._.
        
        
          Immunohistochemistry_NNP of_IN TGF-βs_NNP
          Immunohistochemical_NNP staining_VBG was_VBD done_VBN using_VBG rabbit_NN
          polyclonal_NN antibodies_NNS raised_VBD against_IN synthetic_JJ peptides_NNS
          that_WDT correspond_VB to_TO regions_NNS in_IN the_DT mature_VBP forms_NNS of_IN TGF-β_NNP 
          1_CD ,_, TGF-β_NNP 
          2_CD ,_, and_CC TGF-β_NNP 
          3_CD ._. Antibodies_NNP to_TO TGF-β_NNP 
          1_CD were_VBD raised_VBN against_IN a_DT synthetic_JJ
          peptide_NN corresponding_JJ to_TO residues_NNS 1_CD -_: 30_CD of_IN the_DT mature_VBP
          protein_NN in_IN either_DT the_DT Laboratory_NNP of_IN Chemoprevention_NNP
          (_( anti-_NN TGF-β_NNP 
          1_CD -_: LC_NNP ;_: NIH_NNP ,_, Bethesda_NNP ,_, MD_NNP ,_, USA_NNP )_) or_CC the_DT
          Collagen_NNP Corporation_NNP (_( anti-_NN TGF-β_NNP 
          1_CD -_: CC_NNP ;_: Palo_NNP Alto_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. These_DT
          antibodies_NNS were_VBD raised_VBN against_IN different_JJ preparations_NNS of_IN
          the_DT 1_CD -_: 30_CD peptide_NN ,_, and_CC they_PRP recognize_VBP different_JJ epitopes_NNS
          of_IN this_DT peptide_NN [_NN 19_CD ]_NN ._. The_DT LC_NNP antibody_NN usually_RB stains_NNS
          intracellular_NN TGF-β_NNP 
          1_CD ,_, whereas_IN the_DT CC_NNP antibody_NN stains_NNS
          extracellular_NN TGF-β_NNP 
          1_CD ._. Anti-_NNP TGF-β_NNP 
          2_CD (_( sc-_NN 90_CD ;_: Santa_NNP Cruz_NNP Biotechnologies_NNP
          Inc_NNP )_) was_VBD raised_VBN to_TO a_DT peptide_NN corresponding_JJ to_TO residues_NNS
          72_CD -_: 99_CD of_IN the_DT mature_VBP TGF-β_NNP 
          2_CD ._. Anti-_NNP TGF-β_NNP 
          3_CD (_( anti-_NN 50_CD -_: 60_CD -_: β_NN 
          3_CD -_: LC_NNP )_) was_VBD raised_VBN against_IN residues_NNS
          50_CD -_: 60_CD of_IN mature_VBP TGF-β_NNP 
          3_CD [_NN 20_CD ]_NN ._. Anti-_NNP LTBP_NNP (_( Ab_NNP 39_CD )_) was_VBD raised_VBN
          against_IN the_DT purified_JJ full-length_JJ platelet_NN LTBP_NNP [_NN 21_CD ]_NN ._.
          The_DT antibodies_NNS were_VBD affinity_NN purified_JJ against_IN the_DT
          immunizing_VBG peptide_NN (_( anti-_NN TGF-β_NNP 
          3_LS )_) or_CC against_IN protein_NN A_DT sepharose_NN
          (_( anti-_NN TGF-β_NNP 
          1_CD -_: LC_NNP ,_, anti-_NN TGF-β_NNP 
          1_CD -_: CC_NNP ,_, and_CC anti-_NN TGF-β_NNP 
          2_LS )_) ,_, and_CC have_VBP been_VBN assayed_JJ for_IN
          specificity_NN by_IN Western_JJ blot_NN analysis_NN [_NN 19_CD ,_, 20_CD ,_, 33_CD ]_NN ._. All_DT
          antibodies_NNS reacted_VBD with_IN the_DT appropriate_JJ TGF-β_NNP isoform_NN
          except_IN anti-_NN TGF-β_NNP 
          1_CD -_: CC_NNP ,_, which_WDT showed_VBD some_DT
          cross-reactivity_JJ with_IN TGF-β_NNP 
          3_CD on_IN Western_JJ blots_NNS ._.
          Immunohistochemical_NNP staining_VBG was_VBD performed_VBN using_VBG an_DT
          indirect_JJ immunoperoxidase_NN detection_NN protocol_NN (_( Vectastain_NNP
          Elite_NNP kit_NN ;_: Vector_NNP Laboratories_NNPS )_) following_VBG treatment_NN of_IN
          sections_NNS with_IN hyaluronidase_NN to_TO improve_VB antibody_NN
          penetration_NN ._. Optimal_NNP antibody_NN concentrations_NNS were_VBD
          determined_VBN by_IN titration_NN on_IN select_VB samples_NNS before_IN analysis_NN
          of_IN the_DT full_JJ experimental_JJ set_VBN ._. Staining_NNP was_VBD shown_VBN to_TO be_VB
          specific_JJ in_IN control_NN experiments_NNS in_IN which_WDT either_DT the_DT
          primary_JJ antibody_NN was_VBD preincubated_JJ with_IN a_DT 50_CD -_: fold_VB molar_NN
          excess_NN of_IN immunizing_VBG peptide_NN before_IN being_VBG applied_VBN to_TO the_DT
          section_NN (_( anti-_NN TGF-β_NNP 
          2_CD ,_, anti-_NN TGF-β_NNP 
          3_LS )_) ,_, or_CC the_DT section_NN was_VBD stained_JJ with_IN
          an_DT equivalent_NN concentration_NN of_IN nonimmune_NN rabbit_NN
          immunoglobulin_NN (_( anti-_NN TGF-β_NNP 
          1_CD -_: LC_NNP ,_, anti-_NN TGF-β_NNP 
          1_CD -_: CC_NNP ,_, and_CC anti-_NN LTBP_NNP )_) ._. In_IN analysis_NN of_IN
          the_DT full_JJ experimental_JJ set_VBN ,_, for_IN any_DT given_VBN antibody_NN all_DT
          sections_NNS were_VBD stained_JJ at_IN the_DT same_JJ time_NN so_RB as_IN to_TO be_VB
          directly_RB comparable_JJ ,_, and_CC a_DT normal_JJ mouse_NN embryo_NN section_NN
          was_VBD included_VBN as_IN a_DT positive_JJ control_NN ._. A_DT normal_JJ rabbit_NN
          immunoglobulin_NN control_NN was_VBD also_RB run_VB for_IN the_DT whole_JJ
          set_VBN ._.
        
        
          Quantitation_NNP of_IN immunostaining_VBG
          Two_CD different_JJ systems_NNS were_VBD used_VBN to_TO grade_NN
          immunostaining_VBG ._. For_IN all_DT samples_NNS ,_, staining_VBG of_IN the_DT ducts_NNS
          and_CC periductal_NN stroma_NN were_VBD scored_VBN independently_RB ._. For_IN
          samples_NNS after_IN 6_CD weeks_NNS of_IN chemopreventive_JJ treatment_NN ,_,
          staining_VBG intensity_NN was_VBD scored_VBN on_IN a_DT scale_NN of_IN 0_CD -_: 4_CD +_NN ,_, using_VBG
          the_DT mouse_NN embryo_NN control_NN section_NN as_IN a_DT reference_NN standard_JJ
          for_IN each_DT run_NN ._. Staining_NNP was_VBD scored_VBN in_IN a_DT blinded_JJ manner_NN by_IN
          two_CD independent_JJ observers_NNS ,_, and_CC scores_NNS never_RB differed_VBD by_IN
          more_JJR than_IN one_CD point_NN ._. Discrepancies_NNS were_VBD rescored_JJ by_IN
          consensus_NN ._. Staining_NNP intensity_NN was_VBD plotted_VBD as_IN the_DT mean_JJ ±_NN
          standard_JJ deviation_NN for_IN each_DT experimental_JJ group_NN ._.
        
      
      
        Results_NNS
        
          Chemopreventive_NNP efficacy_NN
          Palpable_NNP mammary_JJ tumors_NNS were_VBD first_RB detected_VBD after_IN
          approximately_RB 35_CD days_NNS following_VBG initation_NN with_IN NMU_NNP ,_, and_CC
          by_IN 70_CD days_NNS incidence_NN had_VBD reached_VBN 100_CD %_NN in_IN rats_NNS not_RB treated_VBN
          with_IN chemopreventive_JJ agents_NNS (_( Fig_NNP ._. 1_LS a_DT )_) ._. Tamoxifen_NNP ,_, alone_RB
          or_CC in_IN combination_NN with_IN retinoids_NNS ,_, decreased_VBD tumor_NN
          incidence_NN by_IN more_JJR than_IN 70_CD %_NN by_IN the_DT end_NN of_IN the_DT study_NN ,_,
          whereas_IN 9_CD cRA_NN alone_RB decreased_VBD it_PRP by_IN 50_CD %_NN ._. 4_LS -_: HPR_NNP alone_RB had_VBD a_DT
          relatively_RB modest_JJ effect_NN on_IN tumor_NN incidence_NN in_IN the_DT
          present_JJ study_NN ._. However_RB ,_, it_PRP significantly_RB decreased_VBD tumor_NN
          multiplicity_NN (_( Fig_NNP ._. 1_LS b_SYM )_) indicating_VBG that_IN the_DT dose_NN used_VBN was_VBD
          efficacious_JJ ._. These_DT incidence_NN and_CC multiplicity_NN data_NNS are_VBP
          consistent_JJ with_IN previously_RB published_VBN studies_NNS using_VBG this_DT
          model_NN [_NN 2_CD ,_, 4_CD ,_, 34_CD ]_NN ._. The_DT mean_NN weights_NNS of_IN the_DT rats_NNS in_IN the_DT
          various_JJ experimental_JJ groups_NNS differed_VBD by_IN less_JJR than_IN 10_CD %_NN
          from_IN those_DT of_IN rats_NNS not_RB treated_VBN with_IN a_DT chemopreventive_JJ
          agent_NN ,_, except_IN for_IN the_DT rats_NNS treated_VBN with_IN a_DT combination_NN of_IN
          tamoxifen_NN and_CC 4_CD -_: HPR_NNP ,_, in_IN which_WDT the_DT mean_JJ weight_NN was_VBD
          approximately_RB 15_CD %_NN lower_JJR than_IN the_DT that_IN in_IN untreated_JJ group_NN
          by_IN the_DT end_NN of_IN the_DT study_NN (_( Fig_NNP ._. 1_LS c_SYM )_) ._. This_DT suggests_VBZ that_IN
          there_EX was_VBD minimal_JJ toxicity_NN associated_VBN with_IN the_DT
          chemopreventive_JJ intervention_NN ,_, except_IN in_IN the_DT tamoxifen_NN +_NN
          4_CD -_: HPR_NNP group_NN ,_, in_IN which_WDT mild_JJ toxicity_NN was_VBD observed_VBN ._.
        
        
          Effect_NN of_IN chemopreventive_JJ agents_NNS on_IN TGF-β_NNP
          expression_NN in_IN initiated_VBN mammary_JJ gland_NN
          Figure_NN 2_CD shows_VBZ the_DT typical_JJ immunohistochemical_JJ staining_VBG
          pattern_NN for_IN the_DT TGF-βs_NNP and_CC the_DT LTBP_NNP (_( part_NN of_IN the_DT
          naturally_RB occurring_VBG latent_NN TGF-β_NNP complex_JJ )_) in_IN initiated_VBN
          mammary_JJ glands_NNS of_IN 15_CD -_: week-old_JJ rats_NNS that_WDT had_VBD not_RB been_VBN
          treated_VBN with_IN chemopreventive_JJ agents_NNS ._. All_DT three_CD TGF-β_NNP
          isoforms_NNS and_CC the_DT LTBP_NNP showed_VBD broadly_RB similar_JJ staining_VBG
          patterns_NNS ._. They_PRP were_VBD present_VB both_DT in_IN the_DT ductal_NN epithelium_NN
          and_CC in_IN the_DT periductal_NN stroma_NN ,_, suggesting_VBG that_IN the_DT TGF-βs_NNP
          are_VBP synthesized_JJ by_IN the_DT epithelial_NN cells_NNS ,_, and_CC possibly_RB
          stromal_NN cells_NNS ,_, and_CC are_VBP sequestered_VBN in_IN the_DT extracellular_NN
          matrix_NN ._. This_DT staining_VBG pattern_NN is_VBZ consistent_JJ with_IN a_DT role_NN
          for_IN the_DT TGF-βs_NNP in_IN the_DT maintenance_NN of_IN normal_JJ mammary_JJ
          homeostasis_NNS ._.
          None_NN of_IN the_DT chemopreventive_JJ agents_NNS used_VBN ,_, alone_RB or_CC in_IN
          combination_NN ,_, were_VBD found_VBN to_TO affect_VB expression_NN of_IN any_DT of_IN
          the_DT TGF-β_NNP isoforms_NNS or_CC the_DT LTBP_NNP in_IN either_DT ductal_NN
          epithelium_NN or_CC periductal_NN stroma_NN after_IN 6_CD weeks_NNS of_IN
          chemopreventive_JJ intervention_NN (_( Fig_NNP ._. 3_LS )_) ._. The_DT 6_CD -_: week_NN time_NN
          point_NN was_VBD chosen_VBN as_IN representative_NN of_IN the_DT period_NN of_IN
          preneoplasia_NN ,_, because_IN the_DT majority_NN (_( >_NN 80_CD %_NN )_) of_IN the_DT rats_NNS
          had_VBD no_DT palpable_JJ tumors_NNS at_IN this_DT stage_NN (_( Fig_NNP ._. 1_LS )_) ._. Human_NNP
          clinical_JJ material_NN for_IN biomarker_NN analysis_NN in_IN primary_JJ
          chemoprevention_NN studies_NNS is_VBZ also_RB likely_JJ to_TO comprise_VB normal_JJ
          and_CC initiated_VBN ,_, at-risk_JJ epithelium_NN with_IN some_DT early_JJ
          preneoplastic_JJ changes_NNS ,_, but_CC without_IN evidence_NN of_IN major_JJ
          neoplastic_JJ change_NN ._.
          In_IN the_DT 6_CD -_: week_NN study_NN set_VBD ,_, eight_CD out_IN of_IN 36_CD (_( 22_CD %_NN )_) of_IN the_DT
          glands_NNS sampled_VBN showed_VBD histologic_JJ evidence_NN of_IN hyperplasia_NN ._.
          In_IN addition_NN ,_, one_CD out_IN of_IN 36_CD glands_NNS sampled_VBN had_VBD a_DT lesion_NN
          with_IN the_DT appearance_NN of_IN a_DT ductal_NN carcinoma_NN 
          in_IN situ_NN (_( focal_JJ necrosis_NNS ,_, marked_VBD
          atypia_NN and_CC abundant_JJ mitoses_NNS ,_, placing_VBG it_PRP in_IN the_DT category_NN
          of_IN '_POS mammary_JJ intraepithelial_NN neoplasia_NN '_'' by_IN the_DT Annapolis_NNP
          naming_VBG convention_NN [_NN 22_CD ]_NN )_) ,_, and_CC an_DT additional_JJ one_CD had_VBD an_DT
          invasive_JJ carcinoma_NN ._. Both_DT the_DT 
          in_IN situ_NN and_CC the_DT invasive_JJ carcinomas_NNS
          were_VBD in_IN the_DT control_NN group_NN ._. However_RB ,_, both_DT samples_NNS also_RB had_VBD
          histologically_RB normal_JJ ducts_NNS on_IN the_DT same_JJ slide_NN ,_, which_WDT were_VBD
          scored_VBN for_IN the_DT analysis_NN ._. There_EX was_VBD no_DT difference_NN in_IN
          staining_VBG between_IN the_DT ducts_NNS that_WDT were_VBD proximal_NN to_TO the_DT
          tumor_NN and_CC those_DT that_WDT were_VBD more_JJR distal_NN ,_, and_CC neither_DT were_VBD
          there_EX any_DT differences_NNS in_IN staining_VBG observed_VBN between_IN
          histologically_RB normal_JJ and_CC hyperplastic_JJ ducts_NNS in_IN any_DT of_IN
          the_DT samples_NNS analyzed_VBD (_( data_NNS not_RB shown_VBN )_) ._. Since_IN the_DT focus_NN of_IN
          the_DT present_JJ study_NN was_VBD on_IN TGF-β_NNP expression_NN changes_NNS in_IN the_DT
          preneoplastic_JJ gland_NN ,_, staining_VBG of_IN the_DT tumors_NNS was_VBD not_RB
          scored_VBN for_IN the_DT analysis_NN ,_, but_CC in_IN the_DT two_CD cases_NNS present_JJ ,_,
          the_DT staining_VBG did_VBD not_RB differ_VB significantly_RB from_IN that_DT of_IN
          the_DT surrounding_VBG normal-appearing_JJ ducts_NNS (_( not_RB shown_VBN )_) ._.
          Assuming_VBG that_IN a_DT rat_NN weighs_VBZ approximately_RB 250_CD g_SYM and_CC
          eats_VBZ 10_CD g_SYM of_IN chow_NN each_DT day_NN ,_, the_DT equivalent_NN human_JJ doses_NNS to_TO
          those_DT used_VBN in_IN this_DT study_NN would_MD be_VB approximately_RB 2_CD ._. 5_CD
          mg_NN /_NN day_NN tamoxifen_NN ,_, 2_CD g_SYM /_NN day_NN 4_CD -_: HPR_NNP ,_, and_CC 290_CD mg_NN /_NN day_NN 9_CD cRA_NN ._. The_DT
          human_JJ doses_NNS that_WDT are_VBP currently_RB being_VBG used_VBN in_IN clinical_JJ
          trials_NNS are_VBP 20_CD mg_NN /_NN day_NN for_IN tamoxifen_NN ,_, 0_CD ._. 2_CD -_: 0_CD ._. 4_LS g_SYM /_NN day_NN for_IN
          4_CD -_: HPR_NNP ,_, and_CC 100_CD -_: 250_CD mg_NN /_NN day_NN for_IN 9_CD cRA_NN ._. The_DT different_JJ doses_NNS
          of_IN tamoxifen_NN and_CC 4_CD -_: HPR_NNP used_VBD in_IN humans_NNS and_CC rats_NNS probably_RB
          reflect_VBP interspecies_NNS differences_NNS in_IN pharmacokinetics_NNS ._.
          However_RB ,_, because_IN the_DT efficacious_JJ dose_NN for_IN tamoxifen_NN was_VBD
          10_CD times_NNS lower_JJR in_IN the_DT rat_NN than_IN the_DT dose_NN that_WDT has_VBZ
          previously_RB been_VBN shown_VBN to_TO upregulate_NN TGF-β_NNP 
          1_CD expression_NN in_IN human_JJ breast_NN tumor_NN
          tissue_NN [_NN 23_CD ]_NN ,_, we_PRP looked_VBD at_IN the_DT effect_NN of_IN a_DT higher_JJR dose_NN of_IN
          tamoxifen_NN in_IN the_DT rats_NNS ._. Furthermore_RB ,_, because_IN one_CD study_NN [_NN
          35_CD ]_NN showed_VBD that_IN TGF-β_NNP may_MD be_VB transiently_RB upregulated_JJ
          early_RB after_IN administration_NN of_IN tamoxifen_NN ,_, we_PRP also_RB looked_VBD
          at_IN earlier_JJR time_NN points_NNS ._. In_IN rats_NNS receiving_VBG tamoxifen_NN at_IN 10_CD
          mg_NN /_NN kg_NN per_IN day_NN intragastrically_RB (_( equivalent_JJ to_TO 600_CD mg_NN /_NN day_NN
          for_IN a_DT human_JJ )_) or_CC 1_CD mg_NN /_NN kg_NN per_IN day_NN (_( equivalent_JJ to_TO 60_CD mg_NN /_NN day_NN
          for_IN a_DT human_JJ )_) for_IN either_DT 1_CD day_NN or_CC 3_CD weeks_NNS ,_, again_RB no_DT
          consistent_JJ changes_NNS were_VBD seen_VBN in_IN TGF-β_NNP expression_NN ,_, using_VBG
          either_CC the_DT TGF-β_NNP 
          1_CD -_: CC_NNP or_CC the_DT TGF-β_NNP 
          2_CD antibodies_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Effect_NN of_IN chemopreventive_JJ agents_NNS on_IN the_DT histology_NN
          of_IN the_DT mammary_JJ gland_NN
          While_IN scoring_VBG the_DT immunohistochemical_JJ slides_NNS ,_, we_PRP
          noticed_VBD that_IN the_DT mammary_JJ histology_NN appeared_VBD to_TO be_VB altered_VBN
          in_IN rats_NNS treated_VBN with_IN chemopreventive_JJ agents_NNS ._. Hematoxylin_NNP
          and_CC eosin_NN stained_JJ sections_NNS from_IN the_DT samples_NNS after_IN 6_CD weeks_NNS
          of_IN treatment_NN were_VBD analyzed_VBN by_IN a_DT veterinary_JJ pathologist_NN
          (_( MAE_NNP )_) ._. The_DT mammary_JJ glands_NNS from_IN tamoxifen-treated_JJ rats_NNS
          were_VBD less_RBR developed_JJ than_IN those_DT of_IN untreated_JJ control_NN
          animals_NNS ,_, having_VBG fewer_RBR tertiary_JJ ducts_NNS and_CC terminal_NN
          end-buds_JJ ,_, and_CC could_MD consistently_RB be_VB identified_VBN from_IN a_DT
          blind_JJ data_NN set_VBN (_( Fig_NNP ._. 4_LS )_) ._. By_IN 12_CD weeks_NNS of_IN treatment_NN ,_, all_DT
          three_CD chemopreventive_JJ agents_NNS had_VBD a_DT significant_JJ effect_NN on_IN
          glandular_NN histology_NN ,_, with_IN tamoxifen_NN and_CC 9_CD cRA_NN showing_VBG the_DT
          greatest_JJS suppression_NN of_IN ductal_NN development_NN and_CC lobule_NN
          formation_NN ,_, and_CC 4_CD -_: HPR_NNP showing_VBG a_DT relatively_RB mild_JJ
          effect_NN ._.
        
      
      
        Discussion_NNP
        
          TGF-βs_NNP as_IN candidate_NN biomarkers_NNS
          One_CD major_JJ goal_NN in_IN the_DT field_NN of_IN prevention_NN is_VBZ the_DT
          identification_NN of_IN surrogate_JJ biomarkers_NNS that_WDT might_MD rapidly_RB
          predict_VB the_DT effect_NN of_IN a_DT given_VBN agent_NN on_IN the_DT primary_JJ
          end-point_JJ of_IN cancer_NN incidence_NN ._. There_EX is_VBZ an_DT extensive_JJ
          literature_NN showing_VBG that_DT steroid_NN hormone_NN superfamily_RB
          members_NNS ,_, such_JJ as_IN antiestrogens_NNS and_CC retinoids_NNS ,_, can_MD
          upregulate_NN TGF-β_NNP activity_NN in_IN a_DT variety_NN of_IN systems_NNS [_NN 12_CD ,_,
          13_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ,_, 23_CD ,_, 24_CD ,_, 35_CD ]_NN ._. This_DT suggested_VBD that_IN the_DT
          chemopreventive_JJ action_NN of_IN these_DT agents_NNS against_IN breast_NN
          cancer_NN could_MD be_VB mediated_JJ in_IN part_NN through_IN enhancing_VBG the_DT
          tumor_NN suppressor_NN activity_NN of_IN the_DT endogenous_JJ TGF-β_NNP system_NN ,_,
          and_CC thus_RB that_IN changes_NNS in_IN TGF-β_NNP expression_NN might_MD serve_VB as_IN
          useful_JJ surrogate_JJ end-point_JJ biomarkers_NNS of_IN chemopreventive_JJ
          efficacy_NN ._. However_RB ,_, here_RB we_PRP used_VBD the_DT NMU-induced_NNP rat_NN model_NN
          of_IN mammary_JJ carcinogenesis_NNS to_TO show_VB that_IN the_DT
          chemopreventive_JJ effect_NN of_IN tamoxifen_NN and_CC two_CD retinoids_NNS is_VBZ
          not_RB associated_VBN with_IN any_DT consistent_JJ changes_NNS in_IN TGF-β_NNP
          levels_NNS ,_, at_IN least_JJS as_IN determined_VBN immunohistochemically_RB ._.
        
        
          Comparison_NNP with_IN earlier_JJR studies_NNS
          Most_JJS of_IN the_DT previous_JJ studies_NNS on_IN the_DT regulation_NN of_IN
          TGF-βs_NNP by_IN tamoxifen_NN and_CC retinoids_NNS [_NN 12_CD ,_, 13_CD ,_, 14_CD ,_, 17_CD ]_NN have_VBP
          been_VBN done_VBN in_IN tissue_NN culture_NN ._. Thus_RB ,_, the_DT lack_NN of_IN effect_NN on_IN
          TGF-β_NNP expression_NN in_IN the_DT present_NN 
          in_IN vivo_NN study_NN might_MD reflect_VB the_DT
          dependence_NN of_IN the_DT response_NN on_IN contextual_NN cues_NNS that_WDT are_VBP
          only_RB present_JJ in_IN the_DT artificial_NN 
          in_IN vitro_NN environment_NN ._. In_IN one_CD
          previous_JJ 
          in_IN vivo_NN study_NN [_NN 16_CD ]_NN all-_NN 
          trans_NNS -_: retinoic_JJ acid_NN upregulated_JJ
          TGF-β_NNP expression_NN in_IN rats_NNS ,_, with_IN kinetics_NNS and_CC isoform_NN
          selectivity_NN that_WDT varied_VBD with_IN the_DT target_NN tissue_NN ._. However_RB ,_,
          the_DT rats_NNS were_VBD vitamin_NN A-_NNP deficient_NN ,_, and_CC it_PRP is_VBZ not_RB known_VBN
          whether_IN the_DT same_JJ effects_NNS would_MD be_VB seen_VBN in_IN vitamin_NN
          A-_NNP replete_JJ animals_NNS ,_, such_JJ as_IN were_VBD used_VBN in_IN the_DT present_JJ
          study_NN ,_, or_CC whether_IN the_DT response_NN would_MD vary_VB with_IN the_DT
          specific_JJ retinoid_NN used_VBN ._.
          There_EX are_VBP some_DT data_NNS that_WDT support_NN an_DT effect_NN of_IN
          tamoxifen_NN on_IN upregulation_NN of_IN TGF-βs_NNP 
          in_IN vivo_NN in_IN humans_NNS ._. Three_CD months_NNS of_IN
          tamoxifen_NN treatment_NN was_VBD shown_VBN to_TO cause_VB a_DT consistent_JJ
          induction_NN in_IN extracellular_NN TGF-β_NNP in_IN breast_NN cancer_NN
          biopsies_NNS ,_, when_WRB compared_VBN with_IN pretreatment_NN biopsies_NNS from_IN
          the_DT same_JJ patients_NNS [_NN 23_CD ]_NN ._. Furthermore_RB ,_, complex_JJ effects_NNS of_IN
          tamoxifen_NN on_IN induction_NN of_IN TGF-β_NNP 
          2_CD in_IN the_DT plasma_NN of_IN patients_NNS with_IN
          metastatic_JJ breast_NN cancer_NN have_VBP been_VBN described_VBN [_NN 24_CD ]_NN ._. It_PRP is_VBZ
          possible_JJ that_DT tamoxifen_NN is_VBZ only_RB effective_JJ in_IN inducing_VBG
          TGF-β_NNP in_IN the_DT context_NN of_IN a_DT tumor_NN ,_, and_CC not_RB in_IN normal_JJ or_CC
          initiated_VBN tissue_NN ,_, which_WDT was_VBD the_DT subject_NN of_IN the_DT present_JJ
          study_NN ._. This_DT issue_NN could_MD be_VB reassessed_JJ in_IN preclinical_JJ
          models_NNS using_VBG the_DT same_JJ agents_NNS to_TO treat_VB established_VBN
          proliferative_JJ intraepithelial_NN neoplasia_NN ._. However_RB ,_, for_IN
          ease_NN of_IN tissue_NN acquisition_NN ,_, an_DT optimal_NN surrogate_JJ
          end-point_JJ biomarker_NN in_IN a_DT prevention_NN setting_VBG needs_VBZ to_TO be_VB
          modulated_JJ in_IN normal_JJ or_CC premalignant_NN tissues_NNS ._.
        
        
          Alternative_NNP levels_NNS of_IN regulation_NN of_IN the_DT bioefficacy_NN
          of_IN TGF-βs_NNP
          Interestingly_RB ,_, in_IN cell_NN culture_NN ,_, both_DT tamoxifen_NN and_CC
          all-_NN 
          trans_NNS -_: retinoic_JJ acid_NN have_VBP been_VBN
          shown_VBN [_NN 12_CD ,_, 13_CD ,_, 14_CD ,_, 17_CD ]_NN to_TO increase_VB the_DT fraction_NN of_IN TGF-β_NNP
          in_IN its_PRP$ biologically_RB active_JJ ,_, as_IN opposed_VBN to_TO its_PRP$ latent_NN
          form_NN ._. The_DT current_JJ method_NN for_IN discriminating_VBG between_IN
          active_JJ and_CC latent_NN TGF-β_NNP in_IN tissue_NN samples_NNS requires_VBZ the_DT
          use_NN of_IN frozen_VBN sections_NNS and_CC immunofluorescence_NN techniques_NNS ,_,
          which_WDT are_VBP not_RB practical_JJ for_IN routine_JJ clinical_JJ use_NN [_NN 36_CD ]_NN ._.
          As_IN simpler_JJR assays_NNS become_VBP available_JJ ,_, however_RB ,_, the_DT issue_NN of_IN
          possible_JJ changes_NNS in_IN TGF-β_NNP activation_NN status_NN should_MD be_VB
          readdressed_JJ ._. Retinoids_NNP can_MD also_RB affect_VB cellular_JJ
          responsiveness_NNS to_TO TGF-βs_NNP at_IN the_DT level_NN of_IN receptor_NN
          expression_NN and_CC downstream_JJ events_NNS [_NN 37_CD ,_, 38_CD ]_NN ._. To_TO date_NN ,_,
          expression_NN of_IN TGF-β_NNP receptors_NNS and_CC downstream_JJ signaling_VBG
          components_NNS such_JJ as_IN the_DT Smads_NNP have_VBP not_RB been_VBN
          well-characterized_JJ in_IN this_DT rat_NN model_NN ,_, but_CC in_IN our_PRP$
          preliminary_JJ analyses_NNS we_PRP saw_VBD no_DT effect_NN of_IN retinoids_NNS on_IN
          type_NN I_PRP and_CC type_NN II_NNP TGF-β_NNP receptor_NN expression_NN in_IN the_DT
          mammary_JJ gland_NN (_( data_NNS not_RB shown_VBN )_) ._. At_IN this_DT time_NN ,_, however_RB ,_, we_PRP
          certainly_RB cannot_NN rule_NN out_RP the_DT possibility_NN that_DT tamoxifen_NN
          and_CC retinoids_NNS may_MD be_VB having_VBG subtle_JJ effects_NNS on_IN the_DT TGF-β_NNP
          system_NN at_IN levels_NNS other_JJ than_IN the_DT regulation_NN of_IN TGF-β_NNP
          expression_NN ._.
        
        
          Lack_NN of_IN effect_NN of_IN chemopreventive_JJ agents_NNS on_IN TGF-β_NNP
          expression_NN may_MD have_VB positive_JJ implications_NNS
          There_EX is_VBZ considerable_JJ evidence_NN to_TO suggest_VB that_IN ,_, at_IN
          late_JJ stages_NNS in_IN tumorigenesis_NNS ,_, TGF-βs_NNP can_MD actually_RB promote_VB
          the_DT tumorigenic_JJ process_NN ,_, particularly_RB if_IN the_DT epithelial_NN
          cells_NNS have_VBP lost_VBN responsiveness_NNS to_TO the_DT growth_NN regulatory_JJ
          effects_NNS of_IN TGF-β_NNP by_IN this_DT time_NN [_NN 9_CD ,_, 39_CD ,_, 40_CD ,_, 41_CD ]_NN ._. Thus_RB ,_,
          advanced_VBD human_JJ tumors_NNS show_VBP increased_VBN levels_NNS of_IN TGF-β_NNP
          expression_NN [_NN 42_CD ,_, 43_CD ,_, 44_CD ]_NN ,_, and_CC TGF-βs_NNP are_VBP known_VBN to_TO
          suppress_VB the_DT immunosurveillance_NN system_NN ,_, to_TO enhance_VB
          angiogenesis_NNS ,_, invasion_NN and_CC metastasis_NNS ,_, and_CC to_TO increase_VB
          drug_NN resistance_NN [_NN 45_CD ,_, 46_CD ,_, 47_CD ,_, 48_CD ]_NN ._.
          In_IN the_DT colon_NN ,_, loss_NN of_IN the_DT type_NN II_NNP TGF-β_NNP receptor_NN
          occurs_VBZ at_IN the_DT late_JJ adenoma_NN to_TO carcinoma_NN transition_NN [_NN 49_CD ]_NN ,_,
          suggesting_VBG that_IN early_JJ premalignant_NN lesions_NNS retain_VBP TGF-β_NNP
          responsiveness_NNS and_CC would_MD be_VB amenable_JJ to_TO interventions_NNS
          that_WDT enhance_VB TGF-β_NNP activity_NN ._. However_RB ,_, while_IN the_DT present_JJ
          work_NN was_VBD in_IN progress_NN ,_, a_DT study_NN was_VBD reported_VBN [_NN 25_CD ]_NN showing_VBG
          that_DT loss_NN of_IN the_DT type_NN II_NNP TGF-β_NNP receptor_NN can_MD already_RB be_VB
          seen_VBN in_IN a_DT significant_JJ fraction_NN of_IN hyperplasias_NNS without_IN
          atypia_NN in_IN the_DT human_JJ breast_NN ._. Furthermore_RB ,_, loss_NN of_IN the_DT
          receptor_NN correlated_JJ with_IN increased_VBN risk_NN of_IN subsequently_RB
          developing_VBG invasive_JJ breast_NN cancer_NN ._. Thus_RB ,_, unlike_IN in_IN the_DT
          colon_NN ,_, loss_NN of_IN TGF-β_NNP response_NN may_MD be_VB a_DT very_RB early_JJ event_NN
          in_IN the_DT development_NN of_IN human_JJ breast_NN cancer_NN ._.
          Since_IN locally_RB elevated_VBD TGF-β_NNP levels_NNS may_MD select_VB for_IN
          TGF-β-resistant_NNP cells_NNS ,_, and_CC because_IN TGF-βs_NNP can_MD have_VB
          oncogenic_JJ effects_NNS on_IN the_DT stroma_NN ,_, it_PRP may_MD actually_RB be_VB
          important_JJ for_IN the_DT safety_NN profile_NN of_IN chemopreventive_JJ
          agents_NNS to_TO demonstrate_VB that_IN they_PRP do_VBP not_RB increase_VB TGF-β_NNP
          levels_NNS in_IN the_DT at-risk_JJ breast_NN ._. For_IN example_NN ,_, tamoxifen_NN
          resistance_NN in_IN a_DT xenograft_NN model_NN of_IN advanced_VBD human_JJ breast_NN
          cancer_NN ,_, was_VBD recently_RB shown_VBN [_NN 50_CD ]_NN to_TO be_VB associated_VBN with_IN an_DT
          increase_NN in_IN TGF-βs_NNP and_CC concomitant_NN immunosuppressive_JJ
          effects_NNS on_IN natural_JJ killer_NN cells_NNS ._. In_IN this_DT regard_NN ,_, our_PRP$
          demonstration_NN that_IN the_DT expression_NN of_IN TGF-βs_NNP in_IN the_DT
          preclinical_JJ rat_NN model_NN is_VBZ unaffected_JJ by_IN tamoxifen_NN ,_, 9_CD cRA_NN ,_,
          and_CC 4_CD -_: HPR_NNP may_MD actually_RB have_VB positive_JJ implications_NNS ,_,
          because_IN these_DT agents_NNS are_VBP already_RB in_IN clinical_JJ use_NN ._.
        
        
          Limitations_NNPS of_IN the_DT NMU-induced_NNP rat_NN model_NN of_IN mammary_JJ
          carcinogenesis_NNS
          The_DT NMU-induced_NNP rat_NN model_NN of_IN mammary_JJ tumorigenesis_NNS is_VBZ
          widely_RB used_VBN for_IN chemoprevention_NN studies_NNS and_CC yields_NNS rapid_JJ
          development_NN of_IN hormonally_RB responsive_JJ mammary_JJ tumors_NNS with_IN
          100_CD %_NN incidence_NN [_NN 2_CD ,_, 4_CD ,_, 18_CD ]_NN ._. To_TO do_VB this_DT ,_, the_DT initiating_VBG
          agent_NN is_VBZ given_VBN at_IN 8_CD weeks_NNS of_IN age_NN ,_, during_IN early_JJ puberty_NN ,_,
          and_CC the_DT chemopreventive_JJ agent_NN is_VBZ typically_RB given_VBN
          continuously_RB ,_, starting_VBG 1_CD week_NN later_RB ._. Since_IN sexual_JJ
          maturity_NN is_VBZ achieved_VBN at_IN approximately_RB 11_CD weeks_NNS of_IN age_NN in_IN
          rats_NNS ,_, this_DT means_VBZ that_IN the_DT chemopreventive_JJ agent_NN is_VBZ given_VBN
          during_IN a_DT period_NN of_IN active_JJ development_NN of_IN the_DT mammary_JJ
          gland_NN ._.
          In_IN the_DT present_JJ study_NN we_PRP observed_VBD that_IN the_DT histology_NN of_IN
          the_DT tamoxifen-treated_JJ mammary_JJ gland_NN differed_VBD
          significantly_RB from_IN control_NN glands_NNS when_WRB examined_VBD after_IN 6_CD
          weeks_NNS of_IN tamoxifen_NN treatment_NN ._. Specifically_RB ,_, there_EX were_VBD
          fewer_JJR terminal_NN end-buds_JJ and_CC less_RBR tertiary_JJ branching_VBG ,_,
          which_WDT are_VBP indicative_JJ of_IN a_DT delay_NN or_CC arrest_NN in_IN normal_JJ
          mammary_JJ development_NN ._. This_DT is_VBZ consistent_JJ with_IN the_DT known_VBN
          requirement_NN for_IN estrogen_NN for_IN proper_JJ mammary_JJ development_NN [_NN
          51_CD ]_NN ._. We_PRP saw_VBD a_DT lesser_JJR effect_NN with_IN 4_CD -_: HPR_NNP ,_, although_IN this_DT
          type_NN of_IN phenomenon_NN has_VBZ also_RB been_VBN described_VBN in_IN the_DT
          literature_NN for_IN retinoids_NNS [_NN 4_CD ]_NN ._. Thus_RB ,_, part_NN of_IN the_DT
          chemopreventive_JJ efficacy_NN of_IN antiestrogens_NNS and_CC retinoids_NNS
          in_IN this_DT model_NN may_MD be_VB due_JJ to_TO a_DT generalized_JJ decrease_NN in_IN
          ductal_NN development_NN ._. Because_IN chemopreventive_JJ agents_NNS are_VBP
          unlikely_JJ to_TO be_VB given_VBN to_TO humans_NNS during_IN the_DT pubertal_NN
          period_NN ,_, this_DT form_NN of_IN preclinical_JJ model_NN may_MD not_RB accurately_RB
          reflect_VB the_DT degree_NN of_IN chemopreventive_JJ benefit_NN that_WDT could_MD
          be_VB achieved_VBN in_IN humans_NNS ._. Although_IN the_DT accelerated_VBN time_NN
          course_NN and_CC high_JJ penetrance_NN of_IN disease_NN reduces_VBZ the_DT costs_NNS
          of_IN this_DT model_NN ,_, it_PRP may_MD be_VB advisable_JJ to_TO confirm_VB efficacy_NN of_IN
          promising_JJ agents_NNS in_IN a_DT model_NN that_IN delays_NNS application_NN of_IN
          the_DT chemopreventive_JJ agent_NN until_IN the_DT mammary_JJ gland_NN is_VBZ
          fully_RB developed_VBN ._.
        
      
      
        Conclusion_NNP
        We_PRP have_VBP shown_VBN that_DT treatment_NN of_IN rats_NNS with_IN tamoxifen_NN or_CC
        retinoids_NNS results_NNS in_IN effective_JJ chemoprevention_NN of_IN mammary_JJ
        tumorigenesis_NNS ,_, without_IN any_DT detectable_JJ effect_NN on_IN local_JJ
        expression_NN of_IN TGF-βs_NNP ._. Although_IN we_PRP cannot_NN rule_NN out_IN more_JJR
        subtle_JJ effects_NNS on_IN TGF-β_NNP activity_NN ,_, such_JJ as_IN the_DT activation_NN of_IN
        latent_NN forms_NNS ,_, the_DT data_NNS suggest_VBP that_IN the_DT underlying_VBG
        molecular_JJ mechanism_NN of_IN chemoprevention_NN by_IN these_DT agents_NNS does_VBZ
        not_RB involve_VB increases_NNS in_IN TGF-β_NNP expression_NN ._. This_DT agrees_VBZ with_IN
        
        in_IN vitro_NN work_NN showing_VBG that_DT blockade_NN
        of_IN TGF-β_NNP signalling_VBG did_VBD not_RB abrogate_NN the_DT growth_NN inhibitory_NN
        effect_NN of_IN tamoxifen_NN on_IN breast_NN cancer_NN cells_NNS [_NN 26_CD ]_NN ._. Given_VBN the_DT
        very_RB limited_JJ breast_NN tissue_NN available_JJ in_IN clinical_JJ
        chemoprevention_NN trials_NNS ,_, we_PRP do_VBP not_RB recommend_VB testing_NN for_IN
        TGF-βs_NNP as_IN surrogate_JJ end-point_JJ biomarkers_NNS at_IN this_DT time_NN ._.
      
    
  
